Publication | Closed Access

Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer

Breast OncologyMedicinePharmacologyFavorable Safety ProfilesBreast CancerAnti-cancer AgentCancer TreatmentOncologyCell Biology